| Document |
Document Title |
|
WO/2024/111656A1 |
The present invention provides a compound having excellent heat resistance and low dielectric properties, and a curable resin composition and a cured product thereof. The compound is obtained by reacting a compound represented by formu...
|
|
WO/2024/077078A3 |
The present invention provides a method of inhibiting growth of a fungus in a subject, comprising reducing the activity of sterylglucosidase I (SigIl) and/or sterylglucosidase A (SglA) in the fungus.
|
|
WO/2024/112764A1 |
Novel synthetic methods of making pyrrolo[3,4-c]pyrroles, derivatives thereof, and intermediates thereto are provided. Also provided are methods using pyrrolo[3,4-c]pyrroles in the processes for preparing bioactive compounds (e.g. PKR Ac...
|
|
WO/2024/109928A1 |
Provided is a linker-containing antibody drug conjugate. Also involved are a pharmaceutical composition comprising the antibody conjugate, a use of a linker, and a use of the antibody conjugate in the preparation for a drug for preventin...
|
|
WO/2024/112621A1 |
The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said c...
|
|
WO/2024/109665A1 |
The present invention belongs to the field of biomedicines. Disclosed are carbamate-bond-containing lipid compounds and the use thereof. The lipid compounds are compounds of the following structure, the definition of each group being as ...
|
|
WO/2024/067844A9 |
The present application provides a crystal A of fexuprazan hydrochloride. An X-ray powder diffraction pattern thereof has characteristic peaks at positions of 2θvalues of 9.1±0.2°, 13.7±0.2°, 14.9±0.2° and 18.3±0.2°, and has a c...
|
|
WO/2024/103178A1 |
In the absence of vaccines, chemotherapy is the main tool for treating parasitic diseases. As emergent resistant strains limit the utility of the few viable clinical options, new therapy is urgently needed to fight parasitic diseases. Th...
|
|
WO/2024/106781A1 |
The present invention relates to a novel lipid compound and a lipid nanoparticle (LNP) composition containing same. The lipid compound according to the present invention can either directly or indirectly bind to and surround an active su...
|
|
WO/2024/103319A1 |
Provided is a method for synthesizing methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexyl-2-carboxyla
te hydrochloride. The method route is as follows: formula (I). The method of the present invention has the characteristics that the...
|
|
WO/2024/107434A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof,...
|
|
WO/2024/105007A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer tautomer or N-oxide thereof, ...
|
|
WO/2024/098210A1 |
The present invention relates to the technical field of drug research and development, and specifically relates to an aryl carboxylic acid compound, in particular to a use of the aryl carboxylic acid compound in the preparation of an Mrg...
|
|
WO/2024/101234A1 |
The present invention provides a bismaleimide in which an amino group of a dimer diamine has been maleimidized, wherein mixing compatibility and handling ability have been sufficiently enhanced when mixed with other agents such as a cura...
|
|
WO/2024/095078A1 |
Compositions are provided, including a mixture of isomers of itaconimide norbornene and citraconimide norbornene. Copolymers can be formed using the compositions and optionally at least one additional norbornene monomer. Additionally, fi...
|
|
WO/2024/097831A1 |
Provided herein are, inter alia, unnatural amino acids, proteins comprising unnatural amino acids, biomolecule conjugates, and methods of making the unnatural amino acids, proteins, and biomolecule conjugates. In embodiments, the unnatur...
|
|
WO/2024/095863A1 |
The purpose of the present invention is to provide a metal-organic framework (MOF) which readily adsorbs a target substance even when under relatively low pressure. The present invention is a metal-organic framework constituted by specif...
|
|
WO/2024/095862A1 |
The purpose of the present invention is to provide an MOF which has excellent desorption performance. The present invention provides a metal organic framework which is composed of a specific organic ligand and a specific metal ion, where...
|
|
WO/2024/089159A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, pharmaceutical compositions comprising the compounds and methods for synthesising compounds according to formula I. This invention further...
|
|
WO/2024/089272A1 |
The present invention relates to the prevention and/or treatment of protein tyrosine kinase mediated diseases, in particular phosphatidylinositol 3-kinases (PI3Ks) mediated diseases. PI3Ks are well-known as oncology targets and several i...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/092011A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2024/092185A1 |
Provided herein are compounds useful for treating a viral infection caused by polyomavirus, e.g., by inhibiting polyomavirus replication. Also provided are compositions and methods including the provided compounds.
|
|
WO/2024/091511A1 |
The present application relates to compounds of Formula (I), where R1, R2, X, Y, z1 and z2 are as define herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical compositions comprising...
|
|
WO/2024/092219A1 |
The present disclosure relates to novel compounds comprising self-hydrolyzing maleimide functional groups, salts of these compounds, pharmaceutically acceptable salts of these compounds, methods of making these compounds, and methods of ...
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/092009A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
|
|
WO/2024/090485A1 |
The present invention provides a method for producing a fluorine-containing compound under relatively mild conditions by introducing a fluorine atom into a wide variety of oxygen-containing compounds having a ketone group, an aldehyde gr...
|
|
WO/2024/085386A1 |
It has been identified that an alkynyl amino acid ester derivative preparation method using a photocatalytic reaction, according to the present invention, is simple and enables a linear, cyclic or chiral alkynyl amino acid ester derivati...
|
|
WO/2024/086111A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/078614A1 |
Provided are an amino lipid compound for preparing a lipid nanoparticle for delivering an active ingredient and a preparation method therefor, a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and...
|
|
WO/2024/081762A1 |
Disclosed herein are substituted 5-membered ring molecules substituted with fluorinated benzyl groups and amino acid groups of formula (I), and derivatives thereof. The substituted 5-membered ring molecules have herbicidal activity and c...
|
|
WO/2024/079206A1 |
The present invention relates to crystalline form I and form II of (2S,5R)-5-(2- chlorophenyl)- 1-(2'-methoxy- [1,1 '-biphenyl] -4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/075760A1 |
The present invention addresses the problem of providing: a novel method for producing a N-acetyl-D-galactosamine ligand-oligonucleotide conjugate, particularly a novel method for producing a N-acetyl-D-galactosamine unit; and a novel in...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/077078A2 |
The present invention provides a method of inhibiting growth of a fungus in a subject, comprising reducing the activity of sterylglucosidase I (SigIl) and/or sterylglucosidase A (SglA) in the fungus.
|
|
WO/2024/077087A2 |
The present technology relates generally to compounds for inhibiting M24B aminopeptidases to selectively activating the CARDS inflammasome, an innate immune signaling platform that triggers pyroptotic cell death.
|
|
WO/2024/065043A1 |
Provided are lipids and nanoparticles containing such lipids and a cargo molecule, such as nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The li...
|
|
WO/2024/067304A1 |
The present invention provides a compound with inhibitory activity against Sigma2 and 5HT2A. The compound can be used as a dual-target inhibitor of Sigma2 and 5HT2A for the treatment of a related disease mediated by Sigma2 receptor activ...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/067708A1 |
Provided are an ammonium oxalate compound represented by formula (I) or a pharmaceutically acceptable salt, an ester, an optical isomer, a tautomer, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotopically labeled compound, a m...
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/061348A1 |
The present invention provides a 1,3-cyclohexanedione compound shown in formula I, and a stereoisomer and an agrochemically acceptable salt thereof, wherein R1, R2, R3, and R4 are as defined in the description. Also disclosed are a prepa...
|
|
WO/2024/060356A1 |
The present invention relates to an economical and feasible method for industrially producing a deuterated COVID-19 medicament key intermediate D. The method has low reaction line cost, and high conversion rate, selectivity, reaction yie...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/062310A1 |
The present invention provides derivatives of (2S,3R,4R,5S,6R)-2-[4- chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-phenyl]-6-(
hydroxymethyl)- oxan-3,4,5-triol (empagliflozin) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl...
|
|
WO/2024/059317A1 |
Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
|
|
WO/2024/055801A1 |
The present invention relates to a pyridinamide derivative and a use thereof, and specifically relates to a compound of formula (I) or an isotope labeled compound thereof as a pyridinamide derivative, or an optical isomer, a geometric is...
|
|
WO/2024/056101A1 |
The present invention relates to a linker for an antibody-drug conjugate and a use thereof. Specifically, a linker represented by formula I is provided. An antibody-drug conjugate prepared by means of the linker are more stable and more ...
|
